


Lysaker, May 6(th) 2015 - Reference is made to the previous announcements by PCI
Biotech Holding ASA ("PCI Biotech" or the "Company") 27(th) April 2015 in
respect of exercise of employee share options in the Company and transfer of
rights to a third party.
The primary insider and CEO, Per Walday, transferred a total number of 60 000
rights to receive shares to a third party for a total net compensation of NOK
397 050. This compensation, net of tax, was used to purchase a total number of
17 647 shares at a price of NOK 11.40 per share, totaling to NOK 201 132. The
purchase price has been determined based on the average selling price per share
made by the third party. After this the primary insider, Per Walday, holds a
total of 40 519 shares and 126 000 unexercised options in the Company,
corresponding to 80 000 unexercised options at a strike price of NOK
14.07, 16 000 unexercised options at a strike price of NOK 27.38 and 30 000
unexercised options at a strike price of NOK 27.54 in the Company.

The other employees who transferred rights to a total of 90 000 shares to a
third party have in total purchased 26 470 shares at a price of NOK 11.40 per
share.

In addition, the primary insider and CFO, Ronny Skuggedal, has purchased 10 000
shares at a price of NOK 11.40 per share. After this, Ronny Skuggedal, holds a
total of 10 000 shares and 60 000 unexercised options in the Company,
corresponding to 40 000 unexercised options at a strike price of NOK 13.78 and
20 000 unexercised options at a strike price of NOK 12.53.

For further information, please contact
Ronny Skuggedal, CFO
Mobile: +47 94005757
rs@pcibiotech.no

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


[HUG#1919421] 
    